Avalyn Pharma

Biotechnology Research • Cambridge, Massachusetts, United States • 51-100 Employees

Company overview

Headquarters	Cambridge, Massachusetts, United States
Phone number	+12067070340
Website	avalynpharma.com
NAICS	541714
SIC	283
Employees	51-100
Socials

Key Contacts at Avalyn Pharma

Lyn Baranowski

Chief Executive Officer

Mai Tanaka-Wakefield

Director, Corporate Development

Stanley Tam

Senior Director, Finance

Rachael Jankowich

Director Clinical Operations

Anne Kinney

Director Clinical Operations

Nicole Krupp

Director, Field Based Medicine

Meredith Hart

Director, Scientific Communications & Medical Education

Sebastien Tilleux

Emea Medical Affairs Director

Michelle Palacios

Senior Director- Nonclinical Development And Translational Sciences

Deepthi Nair

Associate Director, Clinical Data Management

Avalyn Pharma Email Formats

Avalyn Pharma uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@avalynpharma.com), used 48.6% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@avalynpharma.com	48.6%
{first name}{last name}	johndoe@avalynpharma.com	45.7%
{last name}{last name}	doedoe@avalynpharma.com	5.7%

About Avalyn Pharma

Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.

Avalyn Pharma revenue & valuation

Annual revenue	$4,000,000
Revenue per employee	$73,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$12,800,000
Total funding	$275,000,000